TY - JOUR
T1 - Multisystem inflammatory syndrome in adults
T2 - A rare sequela of SARS-CoV-2 infection
AU - Ahmad, Faran
AU - Ahmed, Arslan
AU - Rajendraprasad, Sanu S.
AU - Loranger, Austin
AU - Gupta, Sonia
AU - Velagapudi, Manasa
AU - Vivekanandan, Renuga
AU - Nahas, Joseph A.
AU - Plambeck, Robert
AU - Moore, Douglas
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/7
Y1 - 2021/7
N2 - Multisystem inflammatory syndrome in adults (MIS-A) came to attention back in June 2020, when the United States Center for Disease Control and Prevention (CDC) received initial reports regarding patients who had presented delayed and multisystem involvement of the disease, with clinical course resembling multisystem inflammatory syndrome in children (MIS-C). This study introduces a case of MIS-A, where the patient presented 3 weeks after initial COVID-19 exposure. His clinical course was consistent with the working definition of MIS-A as specified by the CDC. Aggressive supportive care in the intensive care unit, utilization of advanced heart failure devices, and immunomodulatory therapeutics (high-dose steroids, anakinra, intravenous immunoglobulin) led to clinical recovery. Management of MIS-A is a topic of ongoing research and needs more studies to elaborate on treatment modalities and clinical predictors.
AB - Multisystem inflammatory syndrome in adults (MIS-A) came to attention back in June 2020, when the United States Center for Disease Control and Prevention (CDC) received initial reports regarding patients who had presented delayed and multisystem involvement of the disease, with clinical course resembling multisystem inflammatory syndrome in children (MIS-C). This study introduces a case of MIS-A, where the patient presented 3 weeks after initial COVID-19 exposure. His clinical course was consistent with the working definition of MIS-A as specified by the CDC. Aggressive supportive care in the intensive care unit, utilization of advanced heart failure devices, and immunomodulatory therapeutics (high-dose steroids, anakinra, intravenous immunoglobulin) led to clinical recovery. Management of MIS-A is a topic of ongoing research and needs more studies to elaborate on treatment modalities and clinical predictors.
UR - http://www.scopus.com/inward/record.url?scp=85107674909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107674909&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2021.05.050
DO - 10.1016/j.ijid.2021.05.050
M3 - Article
C2 - 34044140
AN - SCOPUS:85107674909
VL - 108
SP - 209
EP - 211
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
SN - 1201-9712
ER -